Predicting distant metastasis and chemoresistance using plasma miRNAs

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Chen, Jianmei ^a   Wang, Weining ^b   Zhang, Yangde ^a   Chen, Yuxiang ^a   Hu, Tiehui ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b First Hospital of Changsha City   (China)

Author keywords

Chemoresistance; Colon cancer; Metastasis; miRNA; Plasma; Prognosis

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; MICRORNA 155; MICRORNA 200C; MICRORNA 210; OXALIPLATIN; ANTINEOPLASTIC AGENT; MICRORNA; MIRN155 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; MIRN210 MICRORNA, HUMAN;

BIOLOGICAL MONITORING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REVIEW; THERAPY RESISTANCE; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; MALE; METASTASIS; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84888772543     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0799-x     Document Type: Review

References (27)

1. Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N, et al. Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer Treat Rev. 2010;36(Suppl 3):S34-41.
2. Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH, Liu JH, et al. Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol. 2010;16:960-5.
3. Ades S. Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology. 2009;23:162-7.
4. Barone C. Adjuvant chemotherapy of colon cancer current strategies. Eur J Cancer. 2008;6(Suppl):60-3.
5. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573-84. (Pubitemid 47106628)
6. Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2012;59:467-74.
7. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515-24. (Pubitemid 43345317)
8. Bagga S, Pasquinelli AE. Identification and analysis of microRNAs. Genet Eng (N Y). 2006;27:1-20.
9. Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010;29:4980-8.
10. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28:369-78.
11. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283:15878-83.
12. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2012;62:1315-26.
13. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS. 2006;103:2257-61. (Pubitemid 43271657)
14. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 2009;1792:497-505.
15. Hofsli E, Sjursen W, Prestvik WS, Johansen J, Rye M, Tranø G, et al. Identification of serum microRNA profiles in colon cancer. Br J Cancer. 2013;108:1712-9.
16. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011;57:833-40.
17. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer. 2013;108:361-9.
18. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006.
19. Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2013;49:604-15.
20. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:1236-43.
21. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights. 2006;2:113-21.
22. Devlin C, Greco S, Martelli F, Ivan M. miR-210: more than a silent player in hypoxia. IUBMB Life. 2011;63:94-100.
23. Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene. 2012;507:135-8.
24. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer. 2013;108:1133-42.
25. Feng B, Wang R, Chen LB. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother. 2012;66:397-402.
26. Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011;17:3029-38.
27. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285:17869-79.